41 active not recruiting. 41 Phase 2, 4 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 41 | Active not recruiting 41 |
| Phase 1 | 4 | Active not recruiting 4 |
| Phase 3 | 3 | Active not recruiting 3 |
Follow Gastroenteritis: new trials by email Literature Review of Gastroenteritis trials Research Report on Gastroenteritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks Vonoprazan, Placebo - Eosinophilic Esophagitis | Phase 2 | Active not recruiting | Phathom Pharmaceuticals, Inc. | 95 | 2025-10-30 | 2026-10-13 |
| A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis SAR442970, Placebo - Ulcerative Colitis | Phase 2 | Active not recruiting | Sanofi | 105 | 2025-07-07 | 2026-10-09 |
| A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis D-2570, Placebo - UC - Ulcerative Colitis, Moderately to Severely Active Ulcerative Colitis | Phase 2 | Active not recruiting | InventisBio Co., Ltd | 120 | 2025-05-22 | 2026-07-17 |
| Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy AZD7798, Placebo - Crohn's Disease | Phase 2 | Active not recruiting | AstraZeneca | 24 | 2024-12-11 | 2026-10-28 |
| A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High Dose - Eosinophilic Esophagitis (EoE) | Phase 2 | Active not recruiting | Uniquity One (UNI) | 184 | 2024-10-16 | 2026-03-20 |
| A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis Eltrekibart, Mirikizumab, Placebo - Ulcerative Colitis, Ulcerative Colitis Chronic | Phase 2 | Active not recruiting | Eli Lilly and Company | 143 | 2024-10-10 | 2026-10-07 |
| Phase IIa Study Evaluating AZD7798 in Crohn's Disease AZD7798, Placebo - Moderate to Severe Crohn's Disease | Phase 2 | Active not recruiting | AstraZeneca | 120 | 2024-08-28 | 2026-10-27 |
| RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer RRx-001, Intensity Modulated Radiation Therapy (IMRT), Cisplatin for injection 100 mg/m2 - Oral Mucositis | Phase 2 | Active not recruiting | EpicentRx, Inc. | 216 | 2024-04-02 | 2026-06-26 |
| A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis TAK-279, Placebo - Ulcerative Colitis | Phase 2 | Active not recruiting | Takeda | 213 | 2024-03-29 | 2026-08-17 |
| Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis emvistegrast, Placebo-to-match emvistegrast - Ulcerative Colitis | Phase 2 | Active not recruiting | Gilead Sciences | 228 | 2024-03-27 | 2026-04-09 |
| A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis Lutikizumab, Adalimumab - Ulcerative Colitis | Phase 2 | Active not recruiting | AbbVie | 156 | 2024-03-23 | 2025-10-07 |
| Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis Budesonide MMX®, Budesonide controlled ileal release (CR) capsules - Microscopic Colitis | Phase 2 | Active not recruiting | University of Calgary | 80 | 2024-03-21 | 2026-10-21 |
| Mesotherapy Treatment of Irritable Bowel Syndrome Mesotherapy with mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate - Inflammatory Bowel Diseases | Phase 2 | Active not recruiting | Polyclinique de l'Europe | 27 | 2024-02-28 | 2025-05-31 |
| Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis Tilpisertib Fosmecarbil, Placebo - Ulcerative Colitis | Phase 2 | Active not recruiting | Gilead Sciences | 176 | 2023-12-05 | 2026-09-11 |
| Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics ALTB-268 - Ulcerative Colitis | Phase 2 | Active not recruiting | AltruBio Inc. | 50 | 2023-12-04 | 2026-05-05 |
| A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA) Rosnilimab, Placebo - Ulcerative Colitis | Phase 2 | Active not recruiting | AnaptysBio, Inc. | 132 | 2023-12-04 | 2025-10-03 |
| Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease Afimkibart - Crohns Disease | Phase 2 | Active not recruiting | Hoffmann-La Roche | 21 | 2023-07-24 | 2026-09-16 |
| A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have Dupilumab - Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD) | Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 22 | 2023-05-03 | 2026-07-01 |
| Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis bacteriophage, Placebo - Shigellosis | Phase 1 / Phase 2 | Active not recruiting | Intralytix, Inc. | 52 | 2023-02-23 | 2025-06-15 |
| RIC-NEC Randomized Controlled Trial Remote ischemic conditioning (RIC) + Standard of Care for NEC, Standard of Care for NEC - Necrotizing Enterocolitis | Phase 2 | Active not recruiting | The Hospital for Sick Children | 78 | 2023-02-09 | 2026-02-03 |
Showing 20 of 41. Sign in to see all of them.
Colitis, Ulcerative (19) · Crohn Disease (8) · Inflammatory Bowel Diseases (4) · Colitis (3) · Eosinophilic Esophagitis (3) · Enterocolitis, Necrotizing (2) · Inflammation (2) · Melanoma (2) · Appendicitis (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Squamous Cell (1) · Colitis, Microscopic (1) · Colonic Diseases (1) · Colorectal Neoplasms (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1)
Digestive System Diseases (40) · Gastrointestinal Diseases (40) · Intestinal Diseases (34) · Inflammatory Bowel Diseases (23) · Colonic Diseases (21) · Colitis (19) · Neoplasms (5) · Neoplasms by Site (5) · Infections (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Eosinophilia (3) · Esophageal Diseases (3) · Esophagitis (3)
guselkumab (4) · Infliximab (2) · dupilumab (2) · golimumab (2) · 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine (1) · ABX464 (1) · Adalimumab (1) · Amitriptyline (1) · Aquamin (1) · Atorvastatin (1) · Biopsy (1) · Budesonide (1) · CT-P13 (1) · Capsules (1) · Cisplatin (1)
Janssen Research & Development, LLC (4) · Sanofi (3) · AstraZeneca (2) · Gilead Sciences (2) · Intralytix, Inc. (2) · AbbVie (1) · Abivax S.A. (1) · AltruBio Inc. (1) · AnaptysBio, Inc. (1) · Eli Lilly and Company (1) · EpicentRx, Inc. (1) · Hoffmann-La Roche (1) · Icahn School of Medicine at Mount Sinai (1) · InventisBio Co., Ltd (1) · M.D. Anderson Cancer Center (1)
United States (33) · Italy (18) · Poland (18) · France (17) · Canada (16) · Germany (15) · Japan (15) · Spain (15) · United Kingdom (15) · Belgium (14) · Hungary (14) · Czechia (12) · Australia (11) · Austria (10) · China (10)
Agostino Pierro, OBE, MD (1) · Alexander Sulakvelidze, PhD (1) · Andrew W Lee, MD (1) · Bram Verstockt, MD (1) · Christopher Ma, MD MPH (1) · David Lin, MD, PhD (1) · Judy H Cho, MD (1) · Long Nguyen, MD, MS (1)
PMID 33310655, PMID 34815288, PMID 35134323, PMID 36273173, PMID 37659673, PMID 37753954, PMID 38104569, PMID 38545091, PMID 38574740, PMID 39148307, PMID 39706209, PMID 40357993, PMID 40574492, PMID 40684778, PMID 41359652, PMID 41834265, PMID 41871904, PMID 42065421, PMID 42065683, PMID 42077070, PMID 42138225, PMID 42634341
2023 (9), 2017 (1), 2018 (1), N01CN00042 (1), P30CA015083 (1), P30CA060553 (1), UG1CA242643 (1)